Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Teriflunomide
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Concord Biotech gets US FDA Nod for Marketing Multiple Sclerosis Drug Teriflunomide
Details : Teriflunomide is a pyrimidine synthesis inhibitor indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease.
Product Name : Teriflunomide-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 07, 2025
Lead Product(s) : Teriflunomide
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mycophenolate Mofetil,Corticosteroids,Cyclosporine
Therapeutic Area : Nephrology
Study Phase : Approved FDF
Sponsor : Lupin Ltd
Deal Size : Inapplicable
Deal Type : Inapplicable
Lupin, Concord, Receive US FDA Approval for Mycophenolate Mofetil Tablets USP
Details : Mycophenolate Mofetil Tablets are indicated for the prophylaxis of organ rejection in recipients of allogeneic kidney, heart or liver transplants, in combination with other immunosuppressants.
Product Name : Mofecon
Product Type : Antibiotic
Upfront Cash : Inapplicable
June 08, 2020
Lead Product(s) : Mycophenolate Mofetil,Corticosteroids,Cyclosporine
Therapeutic Area : Nephrology
Highest Development Status : Approved FDF
Sponsor : Lupin Ltd
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
